175 related articles for article (PubMed ID: 18453043)
1. New formulations approved for children.
AIDS Patient Care STDS; 2008 Jan; 22(1):88. PubMed ID: 18453043
[No Abstract] [Full Text] [Related]
2. [First HIV triple therapy with one tablet].
Dtsch Med Wochenschr; 2000 Feb; 125(8):A22. PubMed ID: 10723466
[No Abstract] [Full Text] [Related]
3. FDA notifications. Tentative approval given for combination of abacavir, lamivudine & zidovudine tablets.
AIDS Alert; 2009 Sep; 24(9):106. PubMed ID: 19928326
[No Abstract] [Full Text] [Related]
4. Generic lamivudine and abacavir approved.
AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043839
[No Abstract] [Full Text] [Related]
5. FDA notifications. Lamivudine/zidovudine combination approved for pediatric use.
AIDS Alert; 2009 Sep; 24(9):105. PubMed ID: 19938311
[No Abstract] [Full Text] [Related]
6. FDA notifications. Tentative approval for fixed-dose combo abacavir/lamivudine.
AIDS Alert; 2009 Feb; 24(2):22. PubMed ID: 19219952
[No Abstract] [Full Text] [Related]
7. FDA notifications. Generic abacavir and lamivudine combo approved.
AIDS Alert; 2008 Oct; 23(10):115. PubMed ID: 18935685
[No Abstract] [Full Text] [Related]
8. Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone.
Moyle GJ
AIDS Read; 2003 Nov; 13(11):528, 533-5. PubMed ID: 14649622
[No Abstract] [Full Text] [Related]
9. Anti-HIV agents. Abacavir--as good as AZT?
TreatmentUpdate; 2003 Oct; 15(6):3-4. PubMed ID: 17216861
[No Abstract] [Full Text] [Related]
10. Triple nuke therapy--results after one year.
TreatmentUpdate; 2001; 12(10):3-4. PubMed ID: 11570063
[No Abstract] [Full Text] [Related]
11. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis.
Moyle GJ; Gazzard BG
AIDS; 2002 May; 16(7):1086-7. PubMed ID: 11953482
[No Abstract] [Full Text] [Related]
12. Retrovir efficacy supplement approved.
AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043841
[No Abstract] [Full Text] [Related]
13. FDA notifications. Tentative approval for generic lamivudine/zidovudine.
AIDS Alert; 2007 Oct; 22(10):119-20. PubMed ID: 18416011
[No Abstract] [Full Text] [Related]
14. Zidovudine + lamivudine: new preparation. Fewer tablets required.
Prescrire Int; 1999 Apr; 8(40):39-40. PubMed ID: 10848057
[TBL] [Abstract][Full Text] [Related]
15. FDA notifications. FDA tentatively approves fixed-dose lamivudine/zidovudine.
AIDS Alert; 2010 Dec; 25(12):142-3. PubMed ID: 21328815
[No Abstract] [Full Text] [Related]
16. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS;
J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982
[TBL] [Abstract][Full Text] [Related]
17. Focusing on the second phase of plasma HIV-1 RNA clearance.
Lafeuillade A; Poggi C; Sayada C; Pellegrino P; Profizi N
AIDS; 1997 Feb; 11(2):264-6. PubMed ID: 9030385
[No Abstract] [Full Text] [Related]
18. Abacavir arm stopped in clinical trial.
James JS
AIDS Treat News; 2003 Apr; (390):6-7. PubMed ID: 12739475
[TBL] [Abstract][Full Text] [Related]
19. FDA notifications. Combination lamivudine and tenofovir tablet approved.
AIDS Alert; 2010 Jan; 25(1):10. PubMed ID: 20140989
[No Abstract] [Full Text] [Related]
20. FDA notifications. FDA approved pediatric efficacy supplement for Retrovir syrup.
AIDS Alert; 2008 Nov; 23(11):128. PubMed ID: 19043870
[No Abstract] [Full Text] [Related]
[Next] [New Search]
